QL1706 + olaparib

This drug is a combination therapy consisting of **QL1706**, a bispecific monoclonal antibody targeting **PD-1 and CTLA-4**, and **olaparib**, a small molecule **PARP inhibitor**. The combination is under investigation as a treatment for advanced solid tumors, specifically advanced triple-negative breast cancer (TNBC) that has recurred after standard therapies. **Olaparib** inhibits poly (ADP-ribose) polymerase (PARP) enzymes (PARP1 and PARP2), leading to impaired DNA repair in cancer cells, particularly those with BRCA mutations, resulting in cancer cell death. **QL1706** is an immunotherapy designed to block the PD-1 and CTLA-4 pathways, thereby enhancing immune response against tumor cells. The combination is intended to potentiate anti-tumor immune activity and exploit vulnerabilities in cancer cell DNA repair pathways. Current data from clinicaltrials.gov and other registries indicate ongoing Phase II clinical trials of QL1706 + olaparib in subjects with advanced triple-negative breast cancer[1][3][4][7][9].

Other names

AZD2281AZD-2281AZD 2281KU-0059436KU0059436KU 0059436